Incyte Corporation · NASDAQ:INCY
Incyte — Technical Presentation (September 2025)
14 slides from Incyte's technical presentation, Sep 17, 2025
Slide 1: Povorcitinib for Moderate to Severe Hidradenitis Suppurativa: Week 24 Interim Phase 3 Results
Presentation #D1T01.1C Povorcitinib for Moderate to Severe Hidradenitis Suppurativa: Week 24 Interim Phase 3 Results Martina L. Porter, MD,1 Antonio Martorell, PhD,2 Christopher J. Sayed, MD,3 Falk G. Bechara, MD,4 Hadar Lev-Tov, MD, MAS,5 Hessel H. van der Zee, MD,6 Jennifer L. Hsiao, MD,7 John W.
Slide 2: Introduction
Introduction ● HS is a chronic, recurrent, debilitating inflammatory condition that causes painful skin nodules and abscesses, leading to tunnels, irreversible tissue damage, and scarring1 – Disease course is marked by flares, which can be unpredictable1 – HS pathophysiology is complex, involving mu
Slide 3: STOP-HS Study Design
STOP-HS Study Design NCT05620823 and NCT05620836 ● Selective Treatment of Oral Povorcitinib STOP-HS1 (N=608) and STOP-HS2 (N=619) In Hidradenitis Suppurativa Study 1 and Screening Placebo-Controlled Period Extension Period Study 2 are identical in design (up to 28 days) (12 weeks) (42 weeks) – N=122
Slide 4: Demographics and Baseline Clinical Characteristics
Demographics and Baseline Clinical Characteristics STOP-HS1 (N=608) STOP-HS2 (N=619) Placebo Povorcitinib 45 mg Povorcitinib 75 mg Placebo Povorcitinib 45 mg Povorcitinib 75 mg Characteristic n=202 n=204 n=202 n=203 n=208 n=208 Age, median (range), y 36.5 (18–71) 36.0 (18–76) 38.5 (18–77) 39.0 (18–6
Slide 5: Povorcitinib Met the Primary Endpoint: HiSCR50 at Week 12
Povorcitinib Met the Primary Endpoint: HiSCR50 at Week 12 ● In both studies, HiSCR50 primary endpoint met statistical significance with both povorcitinib doses vs placebo at Week 12 and continued to improve through Week 24 Placebo 45 mg 75 mg Placebo→45 mg Placebo→75 mg STOP-HS1 STOP-HS2 Placebo-Con
Slide 6: Povorcitinib Achieved High-Level HiSCR Responses
Povorcitinib Achieved High-Level HiSCR Responses ● Povorcitinib met the key secondary endpoint of HiSCR75 at Week 12 in STOP-HS2 ● Responses continued to improve through Week 24 in both studies HiSCR75 HiSCR90 HiSCR100 STOP-HS1 STOP-HS2 Week 12 (NRI) Week 24 (OC) Week 12 (NRI) Week 24 (OC) Placebo P
Slide 7: Povorcitinib Effectively Reduced Draining Tunnels and Flares
Povorcitinib Effectively Reduced Draining Tunnels and Flares ● Povorcitinib improved draining tunnel (dT) counts vs placebo as early as Week 3 Placebo 45 mg 75 mg Percentage Change From Baseline in dT Count (ITT Population) dT100 (Patients With ≥1 dT at Baseline, Pooled) STOP-HS1 STOP-HS2 60 Week 3
Slide 8: Povorcitinib Achieved Greater Improvements in Skin Pain
Povorcitinib Achieved Greater Improvements in Skin Pain Pooled STOP-HS1 and STOP-HS2 ● Povorcitinib reduced pain by the first visit (Week 3) in both studies [statistically significant in STOP-HS2] ● Patients with mild or no pain increased from ~35% at baseline to ~70% by Week 24 ≥3-Point Reduction i
Slide 9: Clinical Response to Povorcitinib 75 mg
Clinical Response to Povorcitinib 75 mg ● 29-year-old female, non-smoker, with Hurley Stage II, 13.4 years’ HS duration, and BMI 39.4 kg/m² – Inadequate response or intolerance to 3 prior biologic treatments ● Patient achieved meaningful reduction in disease activity and symptom burden with 24 weeks
Slide 10: Safety
Safety Placebo-Controlled Period STOP-HS1 (N=608) STOP-HS2 (N=619) Placebo Povorcitinib 45 mg Povorcitinib 75 mg Placebo Povorcitinib 45 mg Povorcitinib 75 mg Patients, n (%) n=202 n=204 n=202 n=203 n=208 n=208 Any TEAE 106 (52.5) 121 (59.3) 134 (66.3) 95 (46.8) 127 (61.1) 129 (62.3) Treatment-relat
Slide 11: Safety up to Week 24
Safety up to Week 24 Extension Period ● Povorcitinib was well tolerated; the safety profile was consistent with that seen in the PC period STOP-HS1 (N=591) STOP-HS2 (N=597) Placebo→45 mg Placebo→75 mg 45 mg 75 mg Placebo→45 mg Placebo→75 mg 45 mg 75 mg Patients, n (%) n=92† n=93† n=204‡ n=202‡ n=90†
Slide 12: Laboratory Abnormalities
Laboratory Abnormalities Pooled STOP-HS1 and STOP-HS2 ● Low rates of grade ≥3 laboratory abnormalities with 24 weeks of povorcitinib treatment Hemoglobin Lymphocytes Neutrophils Platelets Creatine kinase Grade 2: 80 g/L to <LLN Grade 2: 0.5×109/L to <LLN Grade 2: 1.0×109/L to <LLN Grade 2: 50×109/L
Slide 13: Conclusions
Conclusions ● Povorcitinib demonstrated clinically meaningful superiority over placebo in patients with HS within 12 weeks, with continued improvements through Week 24 – Primary endpoint (HiSCR50 at Week 12) was met in both STOP-HS1 and STOP-HS2 across both doses – Greater resolution of draining tun
Slide 14: Thank You For Your Attention
Thank You For Your Attention ● The authors wish to thank the patients and their families, the investigators, and the site personnel who participated in this study ● They also thank Chenwei Tian, PhD, Jennifer Kelley, PhD, and Kurt Brown, MD, of Incyte Corporation (Wilmington, To download Incyte cont